Autolus Therapeutics
AUTL
Autolus Therapeutics (AUTL) earnings history
Most recent quarter
- Fiscal period
- Q2 2026
- Period end
- Jun 30, 2026
- EPS actual
- −$0.15
- EPS estimate
- −$0.19
- EPS surprise
- +22.80%
- Revenue surprise
- +18.49%
- Revenue
- $45.7M
- Revenue estimate
- $38.6M
- Reported
- Aug 11, 2026
Earnings history
| Period | Reported | EPS estimate | EPS actual | Surprise | Revenue | Filing |
|---|---|---|---|---|---|---|
| Q2 2026 | Aug 11, 2026 | −$0.19 | −$0.15 | +22.80% | $45.7M | SEC |
| Q1 2026 | May 14, 2026 | −$0.25 | −$0.27 | −6.72% | $26.2M | SEC |
| Q4 2025 | Mar 27, 2026 | −$0.26 | −$0.34 | −30.82% | $24.3M | SEC |
| Q3 2025 | Nov 12, 2025 | −$0.21 | −$0.30 | −39.93% | $21.2M | SEC |
| Q2 2025 | Aug 12, 2025 | −$0.23 | −$0.18 | +21.94% | $20.9M | SEC |
| Q1 2025 | May 8, 2025 | −$0.24 | −$0.26 | −6.78% | $9.0M | SEC |
| Q4 2024 | Mar 20, 2025 | −$0.21 | −$0.09 | +56.27% | $29,000.00 | SEC |
| Q3 2024 | Nov 12, 2024 | −$0.21 | −$0.31 | −44.66% | $0.00 | SEC |
| Q2 2024 | Aug 8, 2024 | −$0.19 | −$0.22 | −13.11% | $0.00 | SEC |
| Q1 2024 | May 17, 2024 | −$0.08 | −$0.24 | −199.63% | $10.1M | SEC |
| Q4 2023 | Mar 14, 2024 | −$0.25 | −$0.44 | −73.98% | $0.00 | SEC |
| Q3 2023 | Nov 2, 2023 | −$0.25 | −$0.26 | −4.21% | $403,000.00 | SEC |
| Q2 2023 | Aug 3, 2023 | −$0.22 | −$0.26 | −16.33% | $0.00 | SEC |
| Q1 2023 | May 4, 2023 | −$0.27 | −$0.23 | +13.95% | $1.3M | SEC |
| Q4 2022 | Mar 7, 2023 | −$0.27 | −$0.25 | +8.79% | $3.8M | SEC |
| Q3 2022 | Nov 3, 2022 | −$0.47 | −$0.47 | +0.38% | $2.4M | — |
| Q2 2022 | Aug 4, 2022 | −$0.42 | −$0.46 | −9.52% | $0.00 | — |
| Q1 2022 | May 5, 2022 | −$0.49 | −$0.41 | +16.82% | $166,000.00 | — |
| Q4 2021 | Mar 10, 2022 | −$0.39 | −$0.51 | −32.26% | $180,000.00 | — |
| Q3 2021 | Nov 3, 2021 | −$0.51 | −$0.47 | +6.97% | $236,000.00 | — |
Quarterly revenue
Frequently asked questions
When did Autolus Therapeutics (AUTL) last report earnings?
Autolus Therapeutics last reported on Aug 11, 2026, covering fiscal Q2 2026.
Did AUTL beat earnings estimates?
Yes. Autolus Therapeutics reported EPS of −$0.15 for Q2 2026 against a −$0.19 estimate — a 22.80% beat.
How much revenue did AUTL report last quarter?
Autolus Therapeutics reported $45.7M in revenue for Q2 2026, against a consensus estimate of $38.6M.
Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.